Biotechnology

AmplifyBio Celebrates Grand Opening of Manufacturing Enablement Center in New Albany, Ohio

February 1, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / February 1, 2024 / AmplifyBio, a leading commercialization partner for advanced therapies that include cell and gene therapies, proudly announces the successful grand opening of the AmplifyBio Manufacturing Enablement Center (AMEC) in New Albany, Ohio. The milestone event follows the addition of a site dedicated to drug discovery, optimization and characterization work acquired last year in South San Francisco and...

Read more

AltaThera Pharmaceuticals at AF Symposium 2024

January 31, 2024 12:05 PM

AltaThera Pharmaceuticals will present data on Sotalol IV, a treatment that may significantly shorten hospital stays for heart-related illnesses CHICAGO, IL / ACCESSWIRE / January 31, 2024 / AltaThera Pharmaceuticals will be presenting its data at the 29th Annual AF Symposium at the Omni Boston at the Seaport from February 1-3, where company representatives will be available to speak with directly at booth 503. This intensive symposium brings...

Read more

Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health

January 31, 2024 8:38 AM

SALT LAKE CITY, UT / ACCESSWIRE / January 31, 2024 / Inherent Biosciences, Inc. and Genomic Prediction, Inc. (North Brunswick, NJ) are thrilled to announce a comprehensive commercial partnership agreement. This collaboration is set to advance male reproductive health by integrating Inherent Biosciences' groundbreaking Epigenetic Sperm Quality Test (SpermQT™ marketed under the brand Path Fertility) into Genomic Prediction's robust suite of...

Read more

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

January 31, 2024 8:00 AM

~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~ SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the completion of a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead ‘Next Generation' analgesic,...

Read more

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting

January 30, 2024 10:00 AM

DELRAY BEACH, FL / ACCESSWIRE / January 30, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 5th Annual NIH HEAL...

Read more

Lexaria's Submits Investigational New Drug Application

January 30, 2024 8:45 AM

KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 of DehydraTECH-CBD. This IND submission follows a...

Read more

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

January 30, 2024 3:15 AM

Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million (excluding debt and interest payments) Preliminary unaudited financial liability from the...

Read more

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

January 29, 2024 8:00 AM

Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24 Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe chronic pruritus Company outlines near-clinical pipeline of novel antibody technology for multiple immuno-oncology targets and plans an R&D day in 2024 Company fully funded into 2025 with full...

Read more

Ondine Unveils New Research at SPIE Photonics West

January 26, 2024 2:30 AM

VANCOUVER, BC / ACCESSWIRE / January 26, 2024 / Canadian life sciences company Ondine Biomedical Inc. (LON:OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome. 1...

Read more

Center Point Bio-Tech's Launch of Novel Veterinary Diagnostic System Exceeds Expectations

January 24, 2024 6:30 PM

LAS VEGAS, NV / ACCESSWIRE / January 24, 2024 / Center Point Bio-Tech, LLC ("CPB") successfully launched AlphaION at the 2024 Veterinary Meeting & Expo in Orlando, FL, and orders exceeded expectations. AlphaION is a novel, patent-pending veterinary diagnostic system for use in veterinary practices. AlphaION is revolutionary in its use of new technologies to bring more testing options to veterinary practice and its use of lab automation and...

Read more

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

January 24, 2024 9:15 AM

FDA requests meeting to review the Company's technology component and discuss further development and requirements NEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has scheduled two meetings with the U.S. Food and Drug Administration (FDA) to review the Company's progress...

Read more

Lexaria Releases Annual Letter from the CEO

January 24, 2024 8:45 AM

KELOWNA, BC / ACCESSWIRE / January 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX),(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from CEO Chris Bunka as a strategic update to all stakeholders. CEO LETTER TO STAKEHOLDERS According to the Wall Street Journal, near the end of 2023, there were 446 companies listed on the Nasdaq that were trading under $1 and...

Read more

Hippofi Welcomes Scott Bauccio as New Head of Sales for Pur Biologics

January 23, 2024 5:00 AM

IRVINE, CA / ACCESSWIRE / January 23, 2024 / HippoFi's (OTC PINK:ORHB) biotechnology business PUR Biologics, proudly announces Scott Bauccio as its new Head of Sales. Utilizing his 20 years of sales management and his extensive network of industry- leading sales professionals, Bauccio is expanding the company's sales and distribution channels; already securing two new products: PURamnio (selling now) and PURpeptide (launching within 30 days)....

Read more

Biovica Signs Agreement with Palex Group, a Market Leader in Spain and Portugal

January 19, 2024 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / January 19, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement for DiviTum® TKa in Spain and Portugal with the Palex Group, a leading hospital equipment supplier with a proven track record in taking oncology tests and surgical instruments to market in southern Europe. The collaboration aims at making the test available to...

Read more

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

January 18, 2024 9:00 AM

WARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovation can help patients and that's what Windtree Therapeutics Inc. (NASDAQ:WINT) is hoping to accomplish with its new license agreement with Lee's Pharmaceutical (HK) Ltd. Windtree Therapeutics and Lee's Pharmaceutical are teaming up to develop and...

Read more

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

January 17, 2024 9:00 AM

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding Agreement and a Material...

Read more

Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch

January 17, 2024 9:00 AM

Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status NEW YORK, NY / ACCESSWIRE / January 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development...

Read more

Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

January 17, 2024 9:00 AM

TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants. This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron's commitment to advancing the field of...

Read more

Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space

January 17, 2024 8:00 AM

The distress in the psychedelic space contributed to the Company's challenges. The inability of the Company to undertake certain corporate actions (name and symbol change etc.) due to regulatory filing deficiencies from over a decade ago has hampered the ability of the Company to reposition itself. MIAMI, FL / ACCESSWIRE / January 17, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company...

Read more

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

January 16, 2024 9:10 AM

Extensive work program designed to support commercial discussions. KELOWNA, BC / ACCESSWIRE / January 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the...

Read more